Clinical trial for Cancer, Lung
Official title Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
ClinicalTrials.gov ID: NCT06712745
What this study is testing
- What it's testing
- The study aims to see if this new radiotherapy can be given safely to tumors in the central part of the lung without losing its effectiveness.
- Who it's for
- Adults with cancer in the central part of the lung, whether it is a new lung cancer or a spread from another site.
- What's involved
- Participants will receive the ultra‑fractionated stereotactic radiotherapy and will have scheduled visits and medical tests to monitor safety and treatment response.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years of age.
- Histologically proven diagnosis of cancer. At a minimum, the lung tumor in consideration for treatment must be clinically judged as related to the...
- Stage: Tumor (ITV) 1.5 - 5 cm in maximum diameter.
- Tumor entirely within the 2 cm "central zone" or within 1 cm of the mediastinum, esophagus or proximal bronchial tree by investigator assessment.
- Zubrod/ECOG Performance Status 0-2 within 30 days prior to registration.
You likely can't join if
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
- Plans for the patient to receive other local therapy in lung (including standard fractionated radiotherapy and/or surgery) while on this study...
- Females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a...
- Prior administration of anti-VEGF (vascular endothelial growth factor) therapy within 1 year.
See the full eligibility criteria
- Age ≥ 18 years of age.
- Histologically proven diagnosis of cancer. At a minimum, the lung tumor in consideration for treatment must be clinically judged as related to the biopsied site.
- Stage: Tumor (ITV) 1.5 - 5 cm in maximum diameter.
- Tumor entirely within the 2 cm "central zone" or within 1 cm of the mediastinum, esophagus or proximal bronchial tree by investigator assessment.
- Zubrod/ECOG Performance Status 0-2 within 30 days prior to registration.
- Ability to tolerate MRI.
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
- Plans for the patient to receive other local therapy in lung (including standard fractionated radiotherapy and/or surgery) while on this study, except at disease progression.
- Females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.
- Prior administration of anti-VEGF (vascular endothelial growth factor) therapy within 1 year.
The study team makes the final eligibility decision.
Where it is enrolling
- Dallas, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Dallas, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.